Simplifying Medication Access and Affordability with CoverMyMeds

Read Time: 2 Minutes

According to a recent CoverMyMeds patient survey, medication costs are a major concern for many. In fact, 60% of patients discovered their prescription cost more than expected, leading 1 in 4 patients to abandon their medication all together. And with over 20,000 prescription medications approved for marketing in the U.S., the ability to deliver these medications to patients when they need them – and do so in an affordable manner – has become increasingly challenging.

CoverMyMeds – which is part of McKesson – has been at the forefront of breaking down barriers to medication access and affordability for patients. And while they’re best known for revolutionizing the cumbersome prior authorization process, they’ve spent more than 15 years developing and implementing a suite of tech-enabled solutions aimed at solving the most common medication access and affordability challenges patients face.

Beyond prior authorization, CoverMyMeds helps to:

• Simplify and expand patient hub services, which provide comprehensive patient support.
• Offer a broad scope of advanced patient support services and solutions, such as:
• Case management
• Copay savings programs -inclusive of an electronic, automatic copay coupon program and an enrollment-based copay card program.
• Field-based reimbursement and access teams
• Patient assistance programs (PAP) and support
• Non-commercial pharmacy, direct-to-patient dispensing
• Peer-to-peer clinical education through provider nurse educators
• Virtual and in-home clinical services, nursing and education to support patient success
• Tailor its approach to solving medication access and affordability challenges for brands of all sizes.

To learn more about how CoverMyMeds is delivering industry-driven insights, advanced technology and human expertise to break down even more barriers for patients everywhere, we invite you to read their article, Beyond Prior Auth: Unlocking Medication Access and Affordability.